Diabetes: Insulin remains out of reach despite rising drug innovation – Report

Despite growing pharmaceutical investment in diabetes research and new drug development, access to affordable insulin remains a major challenge in low- and middle-income countries (LMICs), including Nigeria, the 2026 Access to Medicine Index has revealed.
The report warned that the growing focus on newer diabetes treatments, particularly GLP-1 medicines, must not overshadow the persistent barriers preventing millions of people from accessing essential insulin.
The 2026 Index, released by the Access to Medicine Foundation in Amsterdam, Netherlands, found that six pharmaceutical companies have 25 diabetes research and development projects, with innovation heavily concentrated on GLP-1 m...